Nxera
NXERA CONTEMPLATIVE RIBBONS 2 8 K

Our Pipeline

We have a broad pipeline of novel drugs that have potential to become first-in-class or best-in-class medicines for a range of diseases.

We are developing molecules both in-house and with partners to ensure that our medicines have the best chances of reaching patients in need.

In-house Programs

Our emerging pipeline of in-house programs comprise multiple drug candidates that address patient populations across our key focus areas of neurology, GI and immunology, metabolic disorders and rare diseases.

PIVLAZ™ (clazosentan)

Marketed

Indication

Prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH

QUVIVIQ™(daridorexant)

Filing

Indication

Insomnia

GPR52 agonist

Phase 1

Indication

Schizophrenia

Modality

Small molecule

Candidate

NXE0048149

EP4 antagonist

Cancer research

Phase 1

Indication

Immuno-oncology

Modality

Small molecule

Candidate

NXE0039732

Partner

Cancer Research UK

EP4 agonist

Phase 1

Indication

Inflammatory Bowel Disease

Modality

Small molecule

Candidate

NXE0033744

Muscarinic M1-preferring agonist (Japan)

Preclinical

Indication

Neurology

Modality

Small molecule

Candidate

NBI-1117567

GPR35 agonist

Preclinical

Indication

Inflammatory bowel disease/GI disorders

Modality

Small molecule

Candidate

NXE0027477